Doxorubicin, DNA torsion, and chromatin dynamics
By Fan Yang, Sheila S. Teves, Christopher Kemp, Steven Henikoff. Biochimica et Biophysica Acta, 2013
686 citations recorded by the source corpus.
Doxorubicin is one of the most important anti-cancer chemotherapeutic drugs, being widely used for the treatment of solid tumors and acute leukemias. The action of doxorubicin and other anthracycline drugs has been intensively investigated during the last several decades, but the mechanisms that have been proposed for cell killing remain disparate and controversial. In this review, we examine the proposed models for doxorubicin action from the perspective of the chromatin landscape, which is altered in many types of cancer due to recurrent mutations in chromatin modifiers. We highlight recent evidence for effects of anthracyclines on DNA torsion and chromatin dynamics that may underlie basic mechanisms of doxorubicin-mediated cell death and suggest new therapeutic strategies for cancer treatment.
Subfields: Anthropology, Cultural Studies, Sociology and Political Science
View Paper: https://www.semanticscholar.org/paper/e1a685a01fa31ad37f66aa0dd98cba018b8c4c60
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Phatsapong Yingchoncharoen
- D. Richardson
- D. Kalinowski
- A. Gielecińska
- M. Kciuk
- S. Mujwar
- D. Kołat
- Ż. Kałuzińska-Kołat
Citations in the corpus
- Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity (2023, background): “It is possible that the unwinding of DNA that occurs as a result of DOX intercalation provides a significant amount of positive torsional stress that destabilize nucleosomes [63].”
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “According to the time of onset, 3 distinct types of cardiotoxicities have been recognized: (1) acute, occurring after a single dose, or a single course, of anthracyclines, with the onset of clinical manifestations within 2 weeks from the end of treatment; (2) early-onset chronic, developing within 1”
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “In fact, Yang et al. (2014b) reported that human oral cancer KB cells incubated with folate receptor-targeted liposomes containing calcein exhibited a 31-fold higher fluorescence intensity in comparison to an incubation with nontargeted calcein containing liposomes.”